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Acid Starvation
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Luis A. J. Mur1, Andrew D. Westwell2 and Karl F. Hoffmann1*
1 Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, United Kingdom, 2 School
of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom
A library of 14 minimally cytotoxic diterpenoid-like compounds (CC50 > 70 µM
on HepG2 human liver cells) was screened against Mycobacterium smegmatis,
Staphylococcus aureus, and Escherichia coli to determine antimicrobial activity. Some
compounds with a phenethyl alcohol (PE) core substituted with a β-cyclocitral derivative
demonstrated anti-mycobacterial activity, with the most active being compound 1
(MIC = 23.4 mg/L, IC50 = 0.6 mg/L). Lower activity was exhibited against S. aureus,
while no activity was displayed against E. coli. Low cytotoxicity was re-confirmed on
HepG2 cells and additionally on RAW 264.7 murine macrophages (SI for both cell
lines > 38). The sub-lethal (IC50 at 6 h) effect of compound 1 on M. smegmatis was
examined through untargeted metabolomics and compared to untreated bacteria and
bacteria treated with sub-lethal (IC50 at 6 h) concentrations of the antituberculosis
drugs ethambutol, isoniazid, kanamycin, and streptomycin. The study revealed that
compound 1 acts differently from the reference antibiotics and that it significantly affects
amino acid, nitrogen, nucleotides and folate-dependent one-carbon metabolism of
M. smegmatis, giving some insights about the mode of action of this molecule. A future
medicinal chemistry optimization of this new anti-mycobacterial core could lead to more
potent molecules.
Keywords: terpenoids, diterpenoids, mycobacteria, tuberculosis, Mycobacterium smegmatis, untargeted
metabolomics
INTRODUCTION
Tuberculosis (TB), a highly infectious disease caused by the Mycobacterium tuberculosis (MTB),
is included amongst the top 10 causes of human mortality according to the World Health
Organization (World Health Organization [WHO], 2018). The first anti-TB agent to be discovered
was streptomycin, but MTB resistance to this drug quickly evolved (Lienhardt et al., 2012). Current
treatment for TB includes a 6-month combination therapy including the first-line drugs rifampicin,
isoniazid, pyrazinamide and ethambutol (Lienhardt et al., 2012). However, multidrug-resistant TB
(MDR-TB) has also developed, requiring affected patients to subsequently undergo 20 months of
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chemotherapy with more toxic second-line drugs; these regimes
are associated with lower treatment success as well as emergence
of additional resistance to certain second line drugs (kanamycin
and fluoroquinolones) and the evolution of extensive drug
resistant (XDR) TB (Mwanzia et al., 2015). As patients affected
by MRD-TB and XDR-TB have low chances of survival, the
discovery of new anti-TB drugs is an urgent priority.
In this study, a library of minimally cytotoxic diterpenoid-
like compounds (CC50 > 70 µM on HepG2 human liver
cells), previously synthesized and tested for anthelmintic activity
(Crusco et al., 2018), was screened against Mycobacterium
smegmatis. M. smegmatis is a non-pathogenic and fast-growing
Mycobacterium that demonstrates drug-response characteristics
comparable to the highly infectious MDR-TB and, for these
characteristics, represents a suitable model for anti-MTB
drug discovery (Chaturvedi et al., 2007). In particular, some
compounds containing a phenethyl alcohol (PE) core substituted
with a β-cyclocitral (cyclohexenyl) derivative showed anti-
mycobacterial activity, with the most active being compound 1
(MIC = 23.4 mg/L, IC50 = 0.6 mg/L). Compounds were also
screened against representative Gram positive (Staphylococcus
aureus) and Gram negative (Escherichia coli) bacteria to ascertain
generic antimicrobial properties. In contrast to M. smegmatis, low
to no activity was found for S. aureus and E. coli suggesting some
degree of diterpenoid selectivity. As PE is a known antimicrobial
(Corre et al., 1990; Lucchini et al., 1990), the anti-mycobacterial
activity of this compound was additionally tested. Here, the MIC
was found to be > 125 mg/L suggesting that the β-cyclocitral
derivative substituent and/or the 4-methoxy aromatic substituent
are essential for the anti-mycobacterial activity.
Metabolomics-based investigations of compound 1’s anti-
mycobacterial activity indicated modulation of amino acid,
nitrogen, nucleotides, and folate-dependent one-carbon
metabolism within the bacteria that was not observed with
other tested established antibiotics. In particular, a condition of
nitrogen/amino acid starvation was identified, which could be at
the base of compound 1’s mode of action.
In conclusion, we found a selective anti-mycobacterial core
that, to the best of our knowledge, has not been explored yet
and whose optimization could bring to the development of
more potent anti-mycobacterial compounds. The mechanism
of action of this class of molecules has been investigated by
untargeted metabolomics revealing a significant decrease in
nitrogen-containing metabolites and a possible nitrogen/amino
acid starvation effect. Further studies will be necessary to confirm
the generated hypothesis and to give new insights on this
family of molecules.
MATERIALS AND METHODS
Chemicals
The diterpenoid library was synthesized as described previously
(Crusco et al., 2018). Chiral compounds (1, 3, 6, 8, 10, 11, 12,
13, and 14) were synthesized and tested as racemic mixtures
(Crusco et al., 2018). After initial screening (see paragraph
below), compound 1 was resynthesized and retested to confirm
the antimicrobial activity. Streptomycin sulfate, ethambutol
dihydrochloride, isoniazid and phenetyl alcohol were obtained
from Sigma. Kanamycin sulfate was obtained from Gibco. All
compounds, the synthetic diterpenoids and the standard anti-
TB drugs, were solubilized as stock solutions of 2.5 mg/mL in
(1:1) methanol/water.
Bacterial Growth, Minimum Inhibitory
Concentration (MIC) Calculation, and
IC50 Determination
All procedures were performed in a biosafety level 2 (BSL2)
cabinet. S. aureus ATCC 29213 and E. coli ATCC 25922 were
cultured in Luria-Bertani (LB) medium at 37◦C with aeration at
200 rpm for 24 h, while M. smegmatis mc2155 was cultured in
LB medium supplemented with 0.2% (v/v) glycerol and 0.05%
(v/v) Tween 80 at 37◦C with aeration at 200 rpm for 48 h.
The stationary phase cultures were then used for minimum
inhibitory concentration (MIC) determination using the broth
microdilution method, in fresh LB medium, in a 96-well plate
(European Committee for Antimicrobial Susceptibility Testing
[EUCAST] of the European Society of Clinical Microbiology
and Infectious Diseases [ESCMID], 2003). All compounds were
tested in triplicate using an initial bacterial concentration of
5.0× 105 colony forming units (CFU)/mL at final concentrations
of 250 mg/L and 125 mg/L (5% and 2.5% v/v methanol).
Compounds with no visible growth at 125 mg/L were further
evaluated with progressing dilutions. The MIC was determined
as the lowest concentration of a compound at which no growth
was visible after 24 h (S. aureus and E. coli) or after 48 h
(M. smegmatis). For compound 1, dilutions were repeated
in three independent experiments where the optical density
(OD600) was measured in a Hidex plate spectrophotometer
and absorbance data were used for the calculation of an IC50
value. The IC50 value represents a compound concentration
that inhibits 50% of bacterial growth (negative control as
100%) and was obtained from a dose response titration (250–
0.09 mg/L). Dose response curves were obtained by non-linear
regression, after log transformation of concentrations and data
normalization using GraphPad Prism 7.02.
Mammalian Cell Culture and MTT Assay
HepG2 human liver cancer cells were grown in BME culture
media with the addition of 10% v/v Fetal Bovine Serum, 1%
v/v MEM non-essential amino acid solution, 1% v/v 200 mM
L-Glutamine, 1% v/v antibiotic/anti-mycotic. RAW 264.7 murine
macrophage cells were grown in DMEM media with the addition
of 10% v/v Fetal Bovine Serum, 1% v/v 200 mM L-Glutamine,
1% v/v antibiotic/anti-mycotic. When ∼80% confluency was
reached, all cells were prepared for MTT viability assays as
previously described (Nur-e-alam et al., 2017; Crusco et al.,
2018). Briefly, 2.5 × 104 cells per well were cultured in a black
walled 96-well microtiter plate (Fisher Scientific, Loughborough,
United Kingdom) and incubated for 24 h at 37◦C in a humidified
atmosphere with 5% CO2. Test compounds were then titrated
from 100 to 3.13 µM (1.25 final % DMSO) and negative (DMSO;
1.25%) and positive (1% v/v Triton X-100) (Dayeh et al., 2004)
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TABLE 1 | Physicochemical properties and antibacterial activity of compound library.
Compounds Structures RB HBA HBD cLogP MW LRV S. aureus E. coli M. smeg
1 4 2 1 3.90 274.40 0 62.5 >250 23.4
2 4 2 0 4.01 272.38 0 >250 >250 62.5
3 4 2 1 3.88 274.40 0 250 >250 31.25
4 4 2 0 4.01 272.38 0 250 >250 125
5 4 1 0 4.98 284.44 0 >250 >250 250
6 4 1 1 5.12 300.48 1 250 >250 250
7 4 1 0 5.24 298.46 1 62.5 >250 250
8 6 4 1 3.76 334.45 0 >250 >250 >250
9 6 4 0 3.95 332.43 0 >250 >250 >250
10 0 2 0 3.42 256.34 0 >250 >250 >250
11 1 3 0 3.42 286.37 0 >250 >250 >250
12 1 2 0 4.06 272.38 0 >250 >250 125
13 1 1 0 4.69 258.40 0 250 >250 62.5
14 1 1 0 4.70 258.40 0 >250 >250 >250
PE 2 1 1 1.64 122.16 0 NA NA 250
Chemical structures and physicochemical properties of compound library calculated by SwissADME (Daina et al., 2017). RB, number of rotatable bonds; HBA, number
of H-bond acceptors; HBD, number of H-bond donors; cLogP, consensus Log P; MW, molecular weight; and LRV, Lipinski’s rule violations. For predicted good oral
bioavailability, values should be<10,<10,<5,≤5,<500, and≤1, respectively. Minimum inhibitory concentration (MIC; mg/L) of compound library against Staphylococcus
aureus, Escherichia coli and Mycobacterium smegmatis. Values of >250 are considered to indicate no significant antimicrobial activity.
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FIGURE 1 | Principal component analysis (PCA) of treated M. smegmatis metabolome. PCA score plots (n = 6 and 95% confidence interval illustrated, clear outliers
removed) of normalized m/z intensities of metabolites extracted from M. smegmatis treated with compound 1 (1) compared to control bacteria (C) and to bacteria
treated with ethambutol (E), isoniazid (I), kanamycin (K), and streptomycin (S) for 6 h. Plots indicate metabolome differences between treatment groups based on
metabolite features detected by FIE-HRMS in (A) positive and (B) negative ionization mode. Antibiotics with similar mechanism of action were grouped into those
with activity on cell wall (ethambutol and isoniazid, CW) and on protein synthesis (kanamycin and streptomycin, PS) for both (C) positive and (D) negative mode.
Compound 1 did not show any overlap with these antibiotics.
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TABLE 2 | Anti-mycobacterial and cytotoxic activity of compound 1.
Compound MICa Viability of HepG2
cells at MICb (%)
Viability of RAW
cells at MICb (%)
IC50c CC50 on HepG2
cellsa
CC50 on RAW
cellsa
Selectivity Indexd
1 23.4 [85.3] 104 ± 0.14 88 ± 0.29 0.6 (0.2–1.3)[2.2
(0.8–4.8)]
>27.4 [>100] >27.4 [>100] >38.5
aValues expressed as mg/L [µM] and confirmed in triplicate. bValues expressed as average percentage ± SD of three replicates. c IC50 determined from three independent
experiments and expressed as mg/L [µM] with 95% confidence interval. dCalculated from IC50 on M. smegmatis when compared to the CC50 on mammalian cells.
controls included. After a 24 h incubation, the MTT assay was
performed as described (Nur-e-alam et al., 2017; Crusco et al.,
2018) and an IC50 value calculated from absorbance data as
described in the previous paragraph.
Metabolomics Sample Preparation and
Metabolite Extraction
The procedure previously described by Baptista et al. (2018)
was followed with minor modifications. Briefly, a total of 1.5 L
of mycobacterial culture was incubated and grown in constant
shaking at 200 rpm at 37◦C. After 48 h, at OD600 = 0.6, thirty-
six samples (6 biological replicates × 6 treatments; compound 1,
ethambutol, isoniazid, kanamycin, streptomycin and media only
control) of 30 mL bacterial culture (10 mL × each time point;
0, 3, and 6 h) were dosed with compound 1 and antibiotics, at
the concentration able to inhibit 50% of growth at OD600 = 0.6
after 6 h (31.25 mg/L for compound 1, ethambutol and isoniazid,
7.3 mg/L for kanamycin, and streptomycin). At each time point,
an aliquot of 10 mL culture was harvested from each sample,
immersed in liquid nitrogen to quench bacterial metabolism
and stored at -80◦C. In preparation for the extraction, samples
were thawed, centrifuged (10◦C, 4500 rpm), washed with
0.85% NaCl and adjusted to an OD600 of 2. Extraction was
performed by four freeze-thaw cycles and vortexing in 200 µL
of a chloroform/methanol/water 1:3:1 solution. After a final
centrifugation, 100 µL of solution were transferred in mass vials
for flow infusion electrospray high-resolution mass spectrometry
(FIE-HRMS) fingerprinting analysis.
Metabolomics Analysis
FIE-HRMS was performed in the High Resolution Metabolomics
Laboratory (HRML) at Aberystwyth University. A Q-Exactive
Plus mass analyzer equipped with an UltiMate 3000 UHPLC
system (Thermo Fisher Scientific) generated metabolite
fingerprints in positive-negative polarity switching mode.
Ion intensities were acquired between m/z 55 and 1200
in profiling mode at a resolution setting of 280,000 for
3.5 min. An auto sampler injected 20 µl extract into a flow
of 100 µl∗min−1 methanol:water (70:30, v/v). Electro spray
ionization (ESI) source parameter settings were according
to manufacturer’s recommendations. Mass spectra around
the apex of the infusion maximum were combined into a
single mean intensity matrix (runs x m/z) for each ionization
mode using an in-house data aligning routine in Matlab
(R2013b, The MathWorks). Data were log10-transformed before
statistical analysis.
MetaboAnalyst 4.0. – Statistical analysis (Chong et al., 2018)
was used to perform principal component (PCA). MetaboAnalyst
4.0 – MS peaks to pathway (Chong et al., 2018) was used
to identify metabolites (tolerance = 3 ppm) and significant
affected metabolic pathways (model organism = S. aureus).
MetaboAnalyst pathway identification is based on mummichog,
an algorithm able to predict biological activity directly from
mass spectrometry data, avoiding the a priori identification
of metabolites (Li et al., 2013). Mummichog plots all possible
matches in the metabolic network and then looks for local
enrichment, providing reproduction of true activity, as the false
matches will distribute randomly (Li et al., 2013). Examples of
key-metabolites in local enrichment were analyzed for significant
difference (t-test) between control and treatment on Microsoft
Excel and by GraphPad Prism 7.02.
RESULTS AND DISCUSSION
To investigate potential antimicrobial activities of the previously
synthesized diterpenoids (Crusco et al., 2018), a total of 14 related
compounds were analyzed for their physicochemical properties
and screened against S. aureus, E. coli and M. smegmatis
(Table 1). All the compounds showed a predicted good
oral bioavailability and drug-likeness, according to property
predictions performed by SwissADME (Daina et al., 2017) The
most potent antimicrobial activity was found for compound 1
with a MIC of 23.4 mg/L on M. smegmatis, 62.5 mg/L on S. aureus
and no activity on E. coli even at the highest concentration tested
(250 mg/L). When compound 1 was compared to the other
screened analogs, some trends in structure-activity relationship
(SAR) were identified. Replacement of the alcoholic function
(C-OH) with the corresponding oxidized keto form (C = O)
considerably decreased the anti-mycobacterial activity (e.g., 1 vs.
2 and 3 vs. 4), while the presence of the 4-methoxy substituent (-
OCH3) on the phenyl ring was responsible for increased activity
(e.g., 1 vs. 3, 6, 8; 2 vs. 4; 13 vs. 14). As the molecules (1
and 3) sharing the alcoholic functions are structural analogs
of PE, a known antimicrobial (Corre et al., 1990; Lucchini
et al., 1990), this compound was also tested on M. smegmatis.
However, PE was only active at the top concentration tested
(250 mg/L), suggesting that the cyclo-hexenyl substituent and/or
the 4-methoxy aromatic component of compounds 1 and 3
are the critical features associated with the anti-mycobacterial
effects. The role of these substituents in the enhancement
of the anti-mycobacterial activity is currently unknown, but
may be linked to increased hydrophobic interactions of
the molecule with a hypothetical target protein contained
within M. smegmatis.
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As compound 1 demonstrated the best antimicrobial activity
(M. smegmatis > S. aureus > E. coli), it was resynthesized
(Crusco et al., 2018) and used in re-confirmatory experiments.
Here, the anti-mycobacterial activity and the low HepG2 human
liver cell cytoxicity were confirmed (Table 2). Furthermore,
as MTB predominantly resides in alveolar macrophages
(Dheda et al., 2016), compound 1’s effect on RAW 264.7
murine macrophages was also determined (Table 2). Similar
to findings in HepG2 cells, compound 1 exhibited low overt
macrophage cytotoxicity (CC50 > 100 µM) and, consequently,
high anti-mycobacterial selectivity (Table 2).
The activity of compound 1 was further investigated by
examining metabolomic changes following its addition to
M. smegmatis cultures (at its IC50 value at 6 h, 31.25 mg/L)
for 6 h using methodologies previously described by Baptista
et al. (2018) and further assessed in MetaboAnalyst 4.0 (Chong
et al., 2018). Extracted metabolites derived from treated vs
control M. smegmatis were profiled by using FIE-HRMS, a
cutting edge high-throughput method used toward mode
of action studies within bacteria. Unsupervised principal
component analysis (PCA) of the identified m/z features
indicated that the metabolome of bacteria treated with
compound 1 was quite distinct from the metabolome of
bacteria treated with ethambutol, isoniazid, kanamycin, and
streptomycin (each also at IC50 values) as well as untreated
bacteria (Figures 1A,B). Treatment of M. smegmatis with
antibiotics having similar mechanisms of action (cell wall
disruption by inhibition of mycolic acid synthesis for ethambutol
and isoniazid (Chakraborty and Rhee, 2015); protein synthesis
inhibition through binding to the 30 s subunit of ribosomes for
streptomycin and kanamycin (Poulikakos and Falagas, 2013)
showed overlapping metabolomics signatures. Accordingly,
these signatures grouped further into two clusters, and
sample profiles derived from those antibiotics acting on
M. smegmatis cell wall components clustered away from
those affecting protein synthesis (Figures 1C,D). Bacteria
treated with compound 1 did not show any overlapping
metabolomics signature with either the control bacteria
or four antibiotic-treated bacteria, suggesting a different
mechanism of action.
To identify the metabolites responsible for separating control-
and compound 1- treated M. smegmatis samples in PCA (at
6 h), the metabolome data of these two samples was analyzed
using MetaboAnalyst 4.0 (Chong et al., 2018). A total of 1902
m/z features were differentially found between the two samples
in the positive ionization mode, whereas 1456 m/z HRMS
elements were differently present amongst the two samples
in the negative ionization mode (p < 0.001). Examination
on these signatures by MetaboAnalyst 4.0 – MS peaks to
pathway revealed that amino acid-, nitrogen-, nucleotide-
and folate-dependent one-carbon metabolism are the most
significantly affected pathways in M. smegmatis samples treated
with compound 1 (Table 3 for significant different pathways,
Supplementary Information for all identified metabolites and
pathways, Supplementary Tables S1–S4).
Upon further interrogation of the statistically significant
metabolites (Figure 2), most amino acids identified were less
abundant in compound 1 treated M. smegmatis samples when
compared to the controls, as well as metabolites belonging to
nitrogen metabolism and the urea cycle (carbamoyl phosphate,
citrulline, ornithine, glutamate-5-semialdehyde) (Figures 2A,B).
This trend was not observed in the reference antibiotics
treatments (Supplementary Figure S1). Significantly affected
pathways also included pyrimidine metabolism and, on the limit
of significance (p = 0.06), purine metabolism. In particular, most
nucleosides (adenosine, guanosine, cytidine, uridine, thymidine
and their mono and di-phosphate forms) were significantly
less abundant, while some nucleoside metabolic products
(xanthine, xanthosine monophosphate, adenine, phosphoribosyl
pyrophosphate) were found to be more abundant in compound
1 treated M. smegmatis samples compared to controls (Figure 2B
and Supplementary Figure S2A).
TABLE 3 | Significantly affected pathways in M. smegmatis after 6 h treatment with compound 1.
Pathway total Hits total Hits sig (p < 0.05) Hits sig (p < 0.001) EASE FET Gamma
Aminoacyl-tRNA biosynthesisa 66 21 20 17 0.00188 0.00039 0.00127
Glycine, serine, and threonine metabolisma 26 16 15 13 0.00919 0.00198 0.00132
One carbon pool by folatea 7 6 6 6 0.05592 0.00627 0.00162
Valine, leucine, and isoleucine biosynthesisa 26 9 8 7 0.13526 0.03808 0.00233
Nitrogen metabolisma 14 9 9 7 0.13526 0.03808 0.00233
Valine, leucine, and isoleucine degradationa 25 11 9 8 0.13916 0.04582 0.00237
Arginine and proline metabolisma 30 17 16 11 0.13932 0.05897 0.00237
Alanine, aspartate, and glutamate metabolisma 18 13 12 9 0.14059 0.05159 0.00239
Cyanoamino acid metabolisma 8 4 4 4 0.21485 0.03422 0.00336
Valine, leucine, and isoleucine biosynthesisb 26 9 9 8 0.02494 0.00383 0.00234
Pyrimidine metabolismb 33 27 25 16 0.07320 0.03358 0.00286
Purine metabolismb 53 33 29 20 0.11988 0.06469 0.00347
aFrom metabolites identified in positive ionization mode. bFrom metabolites identified in negative ionization mode. Pathways identifications were performed by using
MetaboAnalyst 4.0 (Chong et al., 2018) as described in the Section “Materials and Methods,” after analysis and identification (tolerance = 3 ppm) of m/z features
obtained by FIE-HRMS. The table includes ranked enriched pathways, total number of hits, significant hits (p < 0.05 and p < 0.001), their EASE (Expression Analysis
Systematic Explorer) score (Hosack et al., 2003) their raw p-values (Fisher’s Exact Test, FET) and the p-values using a Gamma distribution (all scores calculated based on
the hits at p < 0.001).
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FIGURE 2 | Mycobacterium smegmatis metabolic networks affected by compound 1. (A) Compound 1 significantly affects amino acid and nitrogen metabolisms. All
the significantly more abundant metabolites are colored in red, while the less abundant metabolites in green (when compared to the control M. smegmatis samples).
Identified hits with no significant changes are in orange. Corresponding names for each metabolite and pathway are also annotated. For pyrimidine, purine and
folate-dependent one-carbon metabolic networks see Supplementary Figure S2. (B) Some key metabolites with significantly (∗p < 0.01, ∗∗p < 0.001) different
concentrations between control and treatment are indicated.
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Collectively, the metabolomics data could suggest that
compound 1, and its related analogs, induces nitrogen and/or
amino acid starvation. This would also impact on purine and
pyrimidine synthesis through their dependence on glutamine and
glutamate. Therefore, the lower concentrations of nucleosides
and the increased concentration of a nucleoside precursor
(phosphoribosyl pyrophosphate) could suggest a downregulation
of nucleoside biosynthesis. Equally, this data could suggest
that increased catabolism is found in compound 1 treated
M. smegmatis as more degradation metabolites including
xanthine, xanthosine monophosphate and adenine are all present
when compared to controls. These findings are in agreement
with previous reported studies which demonstrated, at the
transcriptome level, a downregulation of nucleoside biosynthesis,
and an upregulation of nucleotide catabolism in nitrogen-
starving mycobacteria (Jeßberger et al., 2013; Petridis et al.,
2015). In addition, as folate-dependent one-carbon metabolism
is essential for nucleotide synthesis, our results (Figure 2B and
Supplementary Figure S2B) fit well to a nitrogen-limited intake
hypothesis. This hypothesis is also supported by the significant
decreased concentration of glutamine when compared to 2-
oxo-glutarate (no significant difference) in compound 1 treated
samples (Figure 2B), as the ratio of glutamine/2-oxo-glutarate
is a main sensor of decreased nitrogen levels in mycobacteria
(Gouzy et al., 2014).
Although it is currently not clear how compound 1 causes
the observed nitrogen/ amino acid starvation, some mechanisms
are hypothetically possible. For example, by interacting with cell
membranes (diterpenoids are widely reported to interact with
eukaryotic and prokaryotic cell membranes) (Tsuchiya, 2015),
compound 1 could interfere with ammonium, and/or amino acid
transporters, thereby, decreasing nitrogen intake from external
sources. In support of this hypothesis, terpenoids interfering
with amino acid transport have been previously described in
eukaryotic cells (Wu et al., 2007; Wang et al., 2014; Wibowo
et al., 2018). Whether this can also occur in prokaryotes is
currently unknown, but our metabolomic data suggests it is
a possibility. Alternatively, compound 1 may alter one of the
internal enzymatic systems responsible for nitrogen utilization in
mycobacteria (Gouzy et al., 2014; Petridis et al., 2015) and, thus,
interferes with amino acids synthesis. This could indirectly cause
the overconsumption of available amino acids and nitrogen-
based compounds by alteration of different pathways. The
consequences of nitrogen-limited conditions would negatively
affect protein synthesis (in a different way from kanamycin
and streptomycin, which bind the 30 s subunit of prokaryotic
ribosomes) (Poulikakos and Falagas, 2013) as well as both DNA
and RNA synthesis ultimately leading to bacteria death. However,
further analyses at the molecular level are necessary to give new
indications about the mechanism of action and to eventually
confirm the proposed hypotheses.
In conclusion, a selective anti-mycobacterial core that may
act through direct or indirect alteration of nitrogen/amino
acids metabolism of the mycobacteria was identified.
Further structural modifications of this core could lead to
an optimization of its potency and to the development of new
anti-mycobacterial molecules.
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FIGURE S1 | Mycobacterium smegmatis metabolic networks after reference
antibiotics treatments. Amino acid and nitrogen metabolisms after treatment with
(A) ethambutol, (B) isoniazid, (C) kanamycin and (D) streptomycin. All the
significantly more abundant metabolites are coloured in red, while the less
abundant metabolites in green (when compared to the control M. smegmatis
samples). Identified hits with no significant changes are in orange. Corresponding
names for each metabolite and pathway are also annotated.
FIGURE S2 | Mycobacterium smegmatis metabolic networks affected by
compound 1. Compound 1 significantly affects amino acid and nitrogen (see text,
Figure 2A) and, in addition, (A) pyrimidine and purine and (B) folate-dependent
one-carbon metabolisms. More abundant metabolites are coloured in red, while
the less abundant metabolites are coloured in green (when compared to the
control M. smegmatis samples). Identified hits with no significant changes are in
orange. Corresponding names for each metabolite and pathway are
also annotated.
TABLE S1 | Identification (as KEGG code) of metabolites found by positive
ionization mode after compound 1 treatment.
TABLE S2 | Identification (as KEGG code) of metabolites found by negative
ionization mode after compound 1 treatment.
TABLE S3 | Ranked enriched pathways with total number of hits found by positive
ionization mode after treatment with compound 1, significant hits (p < 0.001), their
EASE (Expression Analysis Systematic Explorer) score (Hosack et al., 2003) their
raw p-values (Fisher’s Exact Test, FET), and the p-values using a Gamma
distribution (all scores calculated based on the hits at p < 0.001).
TABLE S4 | Ranked enriched pathways with total number of hits by negative
ionization mode after treatment with compound 1, significant hits (p < 0.001), their
EASE (Expression Analysis Systematic Explorer) score (Hosack et al., 2003) their
raw p-values (Fisher’s Exact Test, FET), and the p-values using a Gamma
distribution (all scores calculated based on the hits at p < 0.001).
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